Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (viability/apoptosis dataset 1 of 2) - Dataset (ID:20272)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule 1 | Small Molecule 2 | Small Mol 1 Concentration | Small Mol 2 Concentration | Small Mol Conc Unit | Time Point | Time Point Unit | Replicate | Total Number of Cells (Nuclei) | Number of Apoptotic Cells | Relative Viability | Mean Relative Viability | Apoptosis Fraction | Mean Apoptosis Fraction |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 3.160 | uM | 72 | hr | 1 | 955 | 894 | 0.0101 | 0.0089 | 0.9361 | 0.9423 |
COLO 858 | Vemurafenib | PF562271 | 3.160 | 3.160 | uM | 72 | hr | 1 | 486 | 455 | 0.0056 | 0.0041 | 0.9362 | 0.9488 |
COLO 858 | Vemurafenib | PF562271 | 1.000 | 3.160 | uM | 72 | hr | 2 | 561 | 526 | 0.0063 | 0.0058 | 0.9376 | 0.9416 |
COLO 858 | Vemurafenib | Dasatinib | 3.160 | 3.160 | uM | 72 | hr | 3 | 1115 | 1046 | 0.0099 | 0.0097 | 0.9381 | 0.9430 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 3.160 | uM | 72 | hr | 3 | 1041 | 978 | 0.0104 | 0.0089 | 0.9395 | 0.9423 |
COLO 858 | Vemurafenib | PF562271 | 1.000 | 3.160 | uM | 72 | hr | 1 | 595 | 559 | 0.0065 | 0.0058 | 0.9395 | 0.9416 |
COLO 858 | Vemurafenib | PF562271 | 3.160 | 1.000 | uM | 72 | hr | 3 | 688 | 647 | 0.0074 | 0.0092 | 0.9404 | 0.9423 |
COLO 858 | Vemurafenib | Dasatinib | 3.160 | 3.160 | uM | 72 | hr | 2 | 1231 | 1160 | 0.0101 | 0.0097 | 0.9423 | 0.9430 |
COLO 858 | Vemurafenib | Saracatinib | 3.160 | 3.160 | uM | 72 | hr | 1 | 661 | 623 | 0.0064 | 0.0054 | 0.9425 | 0.9547 |
COLO 858 | Vemurafenib | Saracatinib | 3.160 | 1.000 | uM | 72 | hr | 2 | 1142 | 1078 | 0.0108 | 0.0099 | 0.9440 | 0.9514 |
COLO 858 | Vemurafenib | Dasatinib | 3.160 | 1.000 | uM | 72 | hr | 3 | 1093 | 1032 | 0.0087 | 0.0084 | 0.9442 | 0.9531 |
COLO 858 | Vemurafenib | Defactinib | 3.160 | 1.000 | uM | 72 | hr | 3 | 1094 | 1034 | 0.0071 | 0.0077 | 0.9452 | 0.9513 |
COLO 858 | Vemurafenib | Saracatinib | 3.160 | 0.316 | uM | 72 | hr | 3 | 759 | 718 | 0.0069 | 0.0093 | 0.9460 | 0.9244 |
COLO 858 | Vemurafenib | PF562271 | 1.000 | 3.160 | uM | 72 | hr | 3 | 477 | 452 | 0.0045 | 0.0058 | 0.9476 | 0.9416 |
COLO 858 | Vemurafenib | PF562271 | 3.160 | 3.160 | uM | 72 | hr | 2 | 424 | 402 | 0.0040 | 0.0041 | 0.9481 | 0.9488 |
COLO 858 | Vemurafenib | Dasatinib | 3.160 | 3.160 | uM | 72 | hr | 1 | 1247 | 1183 | 0.0091 | 0.0097 | 0.9487 | 0.9430 |
COLO 858 | Vemurafenib | Defactinib | 3.160 | 1.000 | uM | 72 | hr | 1 | 1509 | 1433 | 0.0090 | 0.0077 | 0.9496 | 0.9513 |
COLO 858 | Vemurafenib | Dasatinib | 3.160 | 0.316 | uM | 72 | hr | 1 | 1135 | 1078 | 0.0081 | 0.0064 | 0.9498 | 0.9579 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 3.160 | uM | 72 | hr | 2 | 759 | 722 | 0.0061 | 0.0089 | 0.9513 | 0.9423 |
COLO 858 | Vemurafenib | Defactinib | 3.160 | 0.316 | uM | 72 | hr | 3 | 1488 | 1416 | 0.0085 | 0.0082 | 0.9516 | 0.9545 |
COLO 858 | Vemurafenib | PF562271 | 3.160 | 1.000 | uM | 72 | hr | 1 | 1199 | 1142 | 0.0103 | 0.0092 | 0.9525 | 0.9423 |
COLO 858 | Vemurafenib | Defactinib | 3.160 | 0.316 | uM | 72 | hr | 1 | 1556 | 1484 | 0.0085 | 0.0082 | 0.9537 | 0.9545 |
COLO 858 | Vemurafenib | Saracatinib | 3.160 | 1.000 | uM | 72 | hr | 3 | 963 | 919 | 0.0075 | 0.0099 | 0.9543 | 0.9514 |
COLO 858 | Vemurafenib | Dasatinib | 3.160 | 1.000 | uM | 72 | hr | 2 | 1275 | 1218 | 0.0081 | 0.0084 | 0.9553 | 0.9531 |
COLO 858 | Vemurafenib | Saracatinib | 3.160 | 1.000 | uM | 72 | hr | 1 | 1539 | 1471 | 0.0115 | 0.0099 | 0.9558 | 0.9514 |